LT4157876T - Anti-pd-1 antikūnai - Google Patents

Anti-pd-1 antikūnai

Info

Publication number
LT4157876T
LT4157876T LTEPPCT/US2021/033823T LTUS2021033823T LT4157876T LT 4157876 T LT4157876 T LT 4157876T LT US2021033823 T LTUS2021033823 T LT US2021033823T LT 4157876 T LT4157876 T LT 4157876T
Authority
LT
Lithuania
Prior art keywords
antibodies
Prior art date
Application number
LTEPPCT/US2021/033823T
Other languages
English (en)
Inventor
David A. Blair
Nicole K. GARAFFA
Pankaj Gupta
Priyanka Gupta
Fei Han
Aaron KARLAK
Dongmei Liu
Ivo Lorenz
Mouhamadou Lamine MBOW
Miguel E. MORENO-GARCIA
Joseph A. MOZDZIERZ
Kerry L. M. Ralph
Abdulsalam SHAABAN
Della M. WHITE
Helen Haixia Wu
Guangwei Yang
Original Assignee
Boehringer Ingelheim International Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Boehringer Ingelheim International Gmbh filed Critical Boehringer Ingelheim International Gmbh
Publication of LT4157876T publication Critical patent/LT4157876T/lt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2818—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/75—Agonist effect on antigen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Transplantation (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
LTEPPCT/US2021/033823T 2020-05-26 2021-05-24 Anti-pd-1 antikūnai LT4157876T (lt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202063029962P 2020-05-26 2020-05-26
US202063039686P 2020-06-16 2020-06-16
PCT/US2021/033823 WO2021242663A1 (en) 2020-05-26 2021-05-24 Anti-pd-1 antibodies

Publications (1)

Publication Number Publication Date
LT4157876T true LT4157876T (lt) 2024-10-25

Family

ID=76808128

Family Applications (1)

Application Number Title Priority Date Filing Date
LTEPPCT/US2021/033823T LT4157876T (lt) 2020-05-26 2021-05-24 Anti-pd-1 antikūnai

Country Status (30)

Country Link
US (1) US12312405B2 (lt)
EP (2) EP4157876B1 (lt)
JP (2) JP7512433B2 (lt)
KR (1) KR102871588B1 (lt)
CN (1) CN115956087B (lt)
AU (1) AU2021280232A1 (lt)
BR (1) BR112022023989A2 (lt)
CA (1) CA3181776A1 (lt)
CL (1) CL2022003304A1 (lt)
CO (1) CO2022018416A2 (lt)
CR (1) CR20220596A (lt)
DK (1) DK4157876T3 (lt)
DO (1) DOP2022000264A (lt)
EC (1) ECSP22092185A (lt)
ES (1) ES2994127T3 (lt)
FI (1) FI4157876T3 (lt)
HR (1) HRP20241488T1 (lt)
HU (1) HUE069403T2 (lt)
IL (1) IL298431A (lt)
LT (1) LT4157876T (lt)
MA (1) MA59827B1 (lt)
MX (1) MX2022014974A (lt)
PE (1) PE20231076A1 (lt)
PH (1) PH12022553181A1 (lt)
PL (1) PL4157876T3 (lt)
PT (1) PT4157876T (lt)
RS (1) RS66193B1 (lt)
SI (1) SI4157876T1 (lt)
TW (1) TWI859446B (lt)
WO (1) WO2021242663A1 (lt)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
LT4157876T (lt) 2020-05-26 2024-10-25 Boehringer Ingelheim International Gmbh Anti-pd-1 antikūnai
MX2023012899A (es) 2021-05-05 2023-11-08 Immatics Biotechnologies Gmbh Polipeptidos de union a antigeno bma031 mejorados.
AU2023212994A1 (en) * 2022-01-28 2024-08-08 Georgiamune Inc. Antibodies to programmed cell death protein 1 that are pd-1 agonists

Family Cites Families (125)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US266710A (en) 1882-10-31 Fastening for pocket-books
US4179337A (en) 1973-07-20 1979-12-18 Davis Frank F Non-immunogenic polypeptides
US4275149A (en) 1978-11-24 1981-06-23 Syva Company Macromolecular environment control in specific receptor assays
US4318980A (en) 1978-04-10 1982-03-09 Miles Laboratories, Inc. Heterogenous specific binding assay employing a cycling reactant as label
JPS6023084B2 (ja) 1979-07-11 1985-06-05 味の素株式会社 代用血液
US4419446A (en) 1980-12-31 1983-12-06 The United States Of America As Represented By The Department Of Health And Human Services Recombinant DNA process utilizing a papilloma virus DNA as a vector
NZ201705A (en) 1981-08-31 1986-03-14 Genentech Inc Recombinant dna method for production of hepatitis b surface antigen in yeast
US4640835A (en) 1981-10-30 1987-02-03 Nippon Chemiphar Company, Ltd. Plasminogen activator derivatives
US4601978A (en) 1982-11-24 1986-07-22 The Regents Of The University Of California Mammalian metallothionein promoter system
US4560655A (en) 1982-12-16 1985-12-24 Immunex Corporation Serum-free cell culture medium and process for making same
US4657866A (en) 1982-12-21 1987-04-14 Sudhir Kumar Serum-free, synthetic, completely chemically defined tissue culture media
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
DD266710A3 (de) 1983-06-06 1989-04-12 Ve Forschungszentrum Biotechnologie Verfahren zur biotechnischen Herstellung van alkalischer Phosphatase
US4767704A (en) 1983-10-07 1988-08-30 Columbia University In The City Of New York Protein-free culture medium
US4496689A (en) 1983-12-27 1985-01-29 Miles Laboratories, Inc. Covalently attached complex of alpha-1-proteinase inhibitor with a water soluble polymer
US4965199A (en) 1984-04-20 1990-10-23 Genentech, Inc. Preparation of functional human factor VIII in mammalian cells using methotrexate based selection
US4879231A (en) 1984-10-30 1989-11-07 Phillips Petroleum Company Transformation of yeasts of the genus pichia
US4737456A (en) 1985-05-09 1988-04-12 Syntex (U.S.A.) Inc. Reducing interference in ligand-receptor binding assays
EP0206448B1 (en) 1985-06-19 1990-11-14 Ajinomoto Co., Inc. Hemoglobin combined with a poly(alkylene oxide)
GB8516415D0 (en) 1985-06-28 1985-07-31 Celltech Ltd Culture of animal cells
US4927762A (en) 1986-04-01 1990-05-22 Cell Enterprises, Inc. Cell culture medium with antioxidant
GB8610600D0 (en) 1986-04-30 1986-06-04 Novo Industri As Transformation of trichoderma
US4791192A (en) 1986-06-26 1988-12-13 Takeda Chemical Industries, Ltd. Chemically modified protein with polyethyleneglycol
EP0435911B1 (en) 1988-09-23 1996-03-13 Cetus Oncology Corporation Cell culture medium for enhanced cell growth, culture longevity and product expression
FR2646437B1 (fr) 1989-04-28 1991-08-30 Transgene Sa Nouvelles sequences d'adn, leur application en tant que sequence codant pour un peptide signal pour la secretion de proteines matures par des levures recombinantes, cassettes d'expression, levures transformees et procede de preparation de proteines correspondant
EP0402226A1 (en) 1989-06-06 1990-12-12 Institut National De La Recherche Agronomique Transformation vectors for yeast yarrowia
US5122469A (en) 1990-10-03 1992-06-16 Genentech, Inc. Method for culturing Chinese hamster ovary cells to improve production of recombinant proteins
WO1994004679A1 (en) 1991-06-14 1994-03-03 Genentech, Inc. Method for making humanized antibodies
CA2103059C (en) 1991-06-14 2005-03-22 Paul J. Carter Method for making humanized antibodies
PT752248E (pt) 1992-11-13 2001-01-31 Idec Pharma Corp Aplicacao terapeutica de anticorpos quimericos e marcados radioactivamente contra antigenios de diferenciacao restrita de linfocitos b humanos para o tratamento do linfoma de celulas b
US6096871A (en) 1995-04-14 2000-08-01 Genentech, Inc. Polypeptides altered to contain an epitope from the Fc region of an IgG molecule for increased half-life
US6037454A (en) 1996-11-27 2000-03-14 Genentech, Inc. Humanized anti-CD11a antibodies
US5888809A (en) 1997-05-01 1999-03-30 Icos Corporation Hamster EF-1α transcriptional regulatory DNA
US6737056B1 (en) * 1999-01-15 2004-05-18 Genentech, Inc. Polypeptide variants with altered effector function
WO2001014557A1 (en) 1999-08-23 2001-03-01 Dana-Farber Cancer Institute, Inc. Pd-1, a receptor for b7-4, and uses therefor
AR036993A1 (es) 2001-04-02 2004-10-20 Wyeth Corp Uso de agentes que modulan la interaccion entre pd-1 y sus ligandos en la submodulacion de respuestas inmunologicas
JP4249013B2 (ja) 2001-07-31 2009-04-02 佑 本庶 Ｐｄ−１に対し特異性を有する物質
BR0316880A (pt) 2002-12-23 2005-10-25 Wyeth Corp Anticorpos contra pd-1 e usos dos mesmos
WO2004072286A1 (ja) 2003-01-23 2004-08-26 Ono Pharmaceutical Co., Ltd. ヒトｐｄ−１に対し特異性を有する物質
EP1729795B1 (en) 2004-02-09 2016-02-03 Human Genome Sciences, Inc. Albumin fusion proteins
EP2439273B1 (en) 2005-05-09 2019-02-27 Ono Pharmaceutical Co., Ltd. Human monoclonal antibodies to programmed death 1(PD-1) and methods for treating cancer using anti-PD-1 antibodies alone or in combination with other immunotherapeutics
WO2009026472A1 (en) 2007-08-21 2009-02-26 The General Hospital Corporation Methods for inducing tolerance
WO2009067812A1 (en) 2007-11-28 2009-06-04 Universite De Montreal Pd-1 modulation and uses thereof
US8168757B2 (en) 2008-03-12 2012-05-01 Merck Sharp & Dohme Corp. PD-1 binding proteins
WO2010029435A1 (en) 2008-09-12 2010-03-18 Isis Innovation Limited Pd-1 specific antibodies and uses thereof
WO2010029434A1 (en) 2008-09-12 2010-03-18 Isis Innovation Limited Pd-1 specific antibodies and uses thereof
MX2011003195A (es) 2008-09-26 2011-08-12 Dana Farber Cancer Inst Inc Anticuerpos anti-pd-1, pd-l1 y pd-l2 humanos y usos de los mismos.
CA2791930A1 (en) 2010-03-11 2011-09-15 Kerry Louise Tyson Pd-1 antibody
TW201134488A (en) 2010-03-11 2011-10-16 Ucb Pharma Sa PD-1 antibodies
AR083044A1 (es) 2010-09-27 2013-01-30 Regeneron Pharma Anticuerpos anti-cd48 y usos de los mismos
MX344595B (es) 2010-12-31 2016-12-20 Bioatla Llc Humanizacion rapida de anticuerpos.
EP3939613A1 (en) 2011-08-11 2022-01-19 ONO Pharmaceutical Co., Ltd. Therapeutic agent for autoimmune diseases comprising pd-1 agonist
SG11201508528TA (en) 2013-05-02 2015-11-27 Anaptysbio Inc Antibodies directed against programmed death-1 (pd-1)
CN104250302B (zh) 2013-06-26 2017-11-14 上海君实生物医药科技股份有限公司 抗pd‑1抗体及其应用
US10077305B2 (en) 2013-09-10 2018-09-18 Medimmune Limited Antibodies against PD-1 and uses thereof
TWI681969B (zh) 2014-01-23 2020-01-11 美商再生元醫藥公司 針對ｐｄ-１的人類抗體
TWI680138B (zh) 2014-01-23 2019-12-21 美商再生元醫藥公司 抗ｐｄ-ｌ１之人類抗體
JOP20200094A1 (ar) 2014-01-24 2017-06-16 Dana Farber Cancer Inst Inc جزيئات جسم مضاد لـ pd-1 واستخداماتها
CN105330740B (zh) 2014-07-30 2018-08-17 珠海市丽珠单抗生物技术有限公司 抗pd-1抗体及其应用
PL3177644T3 (pl) 2014-08-05 2021-06-14 MabQuest SA Immunologiczne reagenty wiążące do PD-1
TWI595006B (zh) * 2014-12-09 2017-08-11 禮納特神經系統科學公司 抗ｐｄ－１抗體類和使用彼等之方法
DK3237446T3 (en) 2014-12-22 2021-07-26 Pd 1 Acquisition Group Llc Anti-PD-1-antistoffer
HK1254803A1 (zh) 2015-06-23 2019-07-26 Memorial Sloan Kettering Cancer Center 新型pd -1的免疫调节剂
CN106699888B (zh) 2015-07-28 2020-11-06 上海昀怡健康科技发展有限公司 一种pd-1抗体及其制备方法和应用
EP3355920A4 (en) 2015-09-29 2019-05-15 Celgene Corporation PD-1 BINDING PROTEINS AND METHOD OF USE THEREOF
MY190324A (en) 2015-10-02 2022-04-14 Symphogen As Anti-pd-1 antibodies and compositions
MA43018B1 (fr) 2015-10-02 2021-11-30 Hoffmann La Roche Anticorps anti-pd1 et procédés d'utilisation
WO2017079080A1 (en) 2015-11-02 2017-05-11 The Johns Hopkins University Method of preventing organ transplant rejections using agonists to the pd-1 checkpoint pathway
CN106699889A (zh) 2015-11-18 2017-05-24 礼进生物医药科技（上海）有限公司 抗pd-1抗体及其治疗用途
US10759859B2 (en) 2016-01-14 2020-09-01 Bps Bioscience, Inc. Anti-PD-1 antibodies and uses thereof
WO2017189964A2 (en) * 2016-04-29 2017-11-02 Voyager Therapeutics, Inc. Compositions for the treatment of disease
US12145993B2 (en) 2016-06-08 2024-11-19 Shanghai Jiao Tong University School Of Medicine Sequence of antibody heavy chain constant region for enhancing agonistic antibody activity
RU2656181C1 (ru) 2016-07-13 2018-05-31 Закрытое Акционерное Общество "Биокад" Анти-pd-1-антитела, способ их получения и способ применения
EA201990672A1 (ru) 2016-09-14 2019-08-30 Бэйцзин Ханми Фарм. Ко., Лтд. Антитела, специфически связывающиеся с pd-1, и их функциональные фрагменты
RS61204B1 (sr) * 2016-09-14 2021-01-29 Abbvie Biotherapeutics Inc Anti-pd-1 antitela
US10766958B2 (en) 2016-09-19 2020-09-08 Celgene Corporation Methods of treating vitiligo using PD-1 binding antibodies
AU2017329024A1 (en) 2016-09-19 2019-03-21 Celgene Corporation Methods of treating immune disorders using pd-1 binding proteins
WO2018053709A1 (en) 2016-09-21 2018-03-29 Wuxi Biologics (Shanghai) Co., Ltd. The novel monoclonal antibodies to programmed death 1 (pd-1)
CN107840887B (zh) 2016-09-21 2022-03-25 基石药业（苏州）有限公司 一种新的pd-1单克隆抗体
MA49863A (fr) 2016-11-01 2020-06-17 Anaptysbio Inc Anticorps dirigés contre la mort programmée 1 (pd -1)
CN110392694B (zh) 2016-11-02 2023-08-04 震动疗法股份有限公司 针对pd-1的抗体及其用途
WO2018091661A1 (en) 2016-11-18 2018-05-24 Symphogen A/S Anti-pd-1 antibodies and compositions
CN106519034B (zh) 2016-12-22 2020-09-18 鲁南制药集团股份有限公司 抗pd-1抗体及其用途
US11814429B2 (en) 2017-01-06 2023-11-14 Crescendo Biologics Limited Single domain antibodies to programmed cell death (PD-1)
PL3565844T3 (pl) 2017-01-09 2023-06-12 Tesaro Inc. Sposoby leczenia nowotworów złośliwych przeciwciałami anty-pd-1
JP7105238B2 (ja) 2017-01-18 2022-07-22 ジェネンテック， インコーポレイテッド 抗ｐｄ－ｌ１抗体に対するイディオタイプ抗体及びそれらの使用
EP3571231A4 (en) 2017-01-20 2020-12-02 Tayu Huaxia Biotech Medical Group Co., Ltd. ANTI-PD-1 ANTIBODIES AND THEIR USES
CN108341871A (zh) * 2017-01-24 2018-07-31 三生国健药业（上海）股份有限公司 抗pd-1单克隆抗体及其制备方法和应用
KR20190141658A (ko) 2017-03-29 2019-12-24 셀진 코포레이션 Pd-1 결합 단백질을 포함하는 제제 및 이의 제조 방법
US11603407B2 (en) 2017-04-06 2023-03-14 Regeneron Pharmaceuticals, Inc. Stable antibody formulation
JOP20190260A1 (ar) 2017-05-02 2019-10-31 Merck Sharp & Dohme صيغ ثابتة لأجسام مضادة لمستقبل الموت المبرمج 1 (pd-1) وطرق استخدامها
WO2018226580A2 (en) 2017-06-05 2018-12-13 Janssen Biotech, Inc. Antibodies that specifically bind pd-1 and methods of use
WO2018223923A1 (zh) 2017-06-05 2018-12-13 江苏恒瑞医药股份有限公司 Pd-1抗体与vegf配体或vegf受体抑制剂联合在制备治疗肿瘤的药物中的用途
PL3661954T3 (pl) 2017-08-03 2022-05-16 Amgen Inc. Muteiny interleukiny 21 i sposoby leczenia
CN111727197A (zh) 2018-01-12 2020-09-29 美国安进公司 抗pd-1抗体和治疗方法
AR114127A1 (es) 2018-03-02 2020-07-22 Lilly Co Eli Anticuerpos agonistas contra pd-1 y usos de estos
IL277095B2 (en) 2018-03-07 2025-10-01 Pfizer Preparations containing anti-PD-1 antibody
GB201803746D0 (en) 2018-03-08 2018-04-25 Ultrahuman Eight Ltd PD1 binding agents
GB201803745D0 (en) 2018-03-08 2018-04-25 Ultrahuman Eight Ltd PD1 binding agents
WO2019179391A1 (en) 2018-03-19 2019-09-26 Wuxi Biologics (Shanghai) Co., Ltd. Novel bispecific pd-1/ctla-4 antibody molecules
WO2019179390A1 (en) 2018-03-19 2019-09-26 Wuxi Biologics (Shanghai) Co., Ltd. Novel bispecific pd-1/egfr antibody molecules
WO2019179421A1 (en) 2018-03-19 2019-09-26 Wuxi Biologics (Shanghai) Co., Ltd. Novel bispecific pd-1/ctla-4 antibody molecules
WO2019179434A1 (en) 2018-03-20 2019-09-26 Wuxi Biologics (Shanghai) Co., Ltd. Novel bispecific pd-1/cd47 antibody molecules
JP7482031B2 (ja) 2018-03-20 2024-05-13 ウーシー バイオロジクス アイルランド リミテッド 新規の抗ｐｄ－１抗体
WO2019219064A1 (en) 2018-05-17 2019-11-21 Nanjing Leads Biolabs Co.Ltd Antibody binding pd-1 and use thereof
WO2020015722A1 (en) 2018-07-19 2020-01-23 Tayu Huaxia Biotech Medical Group Co., Ltd. Anti-pd-1 antibodies, dosages and uses thereof
CN110734493B (zh) * 2018-07-20 2021-12-17 厦门大学 抗pd-1抗体及其用途
EP3876978A4 (en) 2018-11-07 2022-09-28 Merck Sharp & Dohme Corp. STABLE FORMULATIONS OF PROGRAMMED DEATH RECEPTOR 1 (PD-1) ANTIBODIES AND METHODS OF USE THEREOF
WO2020116636A1 (ja) 2018-12-07 2020-06-11 小野薬品工業株式会社 免疫抑制剤
TW202509079A (zh) 2019-04-04 2025-03-01 日商小野藥品工業股份有限公司 雙特異性抗體
CN110577599A (zh) 2019-05-13 2019-12-17 深圳市润科生物科技有限公司 人源抗程序性死亡-1(pd-1)抗体及其应用
CA3142714A1 (en) 2019-06-05 2020-12-10 Anaptysbio, Inc. Pd-1 agonist and method of using same
US20220252599A1 (en) 2019-07-12 2022-08-11 The Johns Hopkins University Compositions and methods for treating cerebral vasospasm
WO2021025140A1 (ja) 2019-08-08 2021-02-11 小野薬品工業株式会社 二重特異性タンパク質
WO2021034890A1 (en) 2019-08-19 2021-02-25 Pandion Therapeutics, Inc. Targeted immunotolerance with a pd-1 agonist
US20230355757A1 (en) 2019-12-20 2023-11-09 Formycon Ag Formulations of anti-pd1 antibodies
EP4079763A4 (en) 2019-12-20 2023-10-11 Guangdong Feipeng Pharmaceutical Co., Ltd MONOCLONAL ANTIBODY AGAINST HUMAN PROGRAMMED DEATH-1 (PD-1)
CN110787292B (zh) 2020-01-06 2020-04-24 上海复宏汉霖生物技术股份有限公司 一种细胞程序性死亡受体1抗体制剂及其用途
KR20210097882A (ko) 2020-01-30 2021-08-10 삼성바이오에피스 주식회사 안정한 항-pd-1 항체 약제학적 제제
CN113456582B (zh) 2020-03-30 2024-06-14 鲁南制药集团股份有限公司 重组人源化抗pd-1单克隆抗体的液体制剂
KR20230015348A (ko) 2020-05-25 2023-01-31 고에키 자이단 호징 고베 이료 산교 도시 스이신 기코 Th2 개재성 질환을 치료 또는 예방하기 위한 PD-1 작용제 함유 의약 조성물
LT4157876T (lt) 2020-05-26 2024-10-25 Boehringer Ingelheim International Gmbh Anti-pd-1 antikūnai
CN113797330A (zh) 2020-06-11 2021-12-17 三生国健药业（上海）股份有限公司 一种抗pd-1单克隆抗体液体制剂
MY209953A (en) 2020-06-19 2025-08-15 Sinocelltech Ltd Stable formulation for recombinant anti-pd-1 monoclonal antibody
CN111956799A (zh) 2020-09-18 2020-11-20 生物抗素公司 抗pd-1抗体和/或pd-l1抗体在制备治疗帕金森病药物中的应用

Also Published As

Publication number Publication date
TW202216765A (zh) 2022-05-01
HRP20241488T1 (hr) 2025-02-14
US12312405B2 (en) 2025-05-27
PL4157876T3 (pl) 2025-02-03
WO2021242663A1 (en) 2021-12-02
EP4157876B1 (en) 2024-09-04
PE20231076A1 (es) 2023-07-17
EP4157876A1 (en) 2023-04-05
MA59827B1 (fr) 2024-10-31
SI4157876T1 (sl) 2025-01-31
PT4157876T (pt) 2024-10-21
BR112022023989A2 (pt) 2023-02-07
DK4157876T3 (da) 2024-10-28
RS66193B1 (sr) 2024-12-31
CR20220596A (es) 2023-01-23
KR20230015997A (ko) 2023-01-31
CN115956087A (zh) 2023-04-11
HUE069403T2 (hu) 2025-03-28
ECSP22092185A (es) 2023-01-31
KR102871588B1 (ko) 2025-10-17
EP4464383A2 (en) 2024-11-20
JP2024125366A (ja) 2024-09-18
MX2022014974A (es) 2023-01-11
CN115956087B (zh) 2025-11-07
AU2021280232A1 (en) 2022-12-15
CL2022003304A1 (es) 2023-04-14
IL298431A (en) 2023-01-01
TWI859446B (zh) 2024-10-21
CA3181776A1 (en) 2021-12-02
EP4464383A3 (en) 2025-02-26
JP2023528778A (ja) 2023-07-06
JP7512433B2 (ja) 2024-07-08
US20210380696A1 (en) 2021-12-09
FI4157876T3 (fi) 2024-10-25
DOP2022000264A (es) 2023-01-31
PH12022553181A1 (en) 2024-03-04
CO2022018416A2 (es) 2022-12-30
ES2994127T3 (en) 2025-01-17
JP7777632B2 (ja) 2025-11-28

Similar Documents

Publication Publication Date Title
SMT202300397T1 (it) Anticorpi contro sars-cov-2
IL277095A (en) Preparations containing anti-PD-1 antibody
IL308741A (en) Anti-SIRP-alpha antibodies
GB202105110D0 (en) Anti-CD73 antibodies
PT4214240T (pt) Anticorpos anti-ccr8
IL286757A (en) Antibodies in specific
IL286918A (en) Bispecific antibody
PL4157876T3 (pl) Przeciwciała anty-pd-1
GB202014851D0 (en) SARS-COV-2 antibodies
GB202111905D0 (en) Antibodies
IL300142A (en) Anti-IL13Ralpha2 antibodies
ZA202206008B (en) Bispecific anti-ccl2 antibodies
IL290050A (en) Bispecific antibody
GB202015115D0 (en) ZIP12 Antibody
GB201910138D0 (en) Anti-pd-l1 antibodies
GB202008860D0 (en) BTLA antibodies
IL308782A (en) Antibodies
IL308100A (en) Antibodies
GB202105933D0 (en) Anti-IL1rap antibody
GB201906538D0 (en) Anti-pd-1 antibodies
GB202208773D0 (en) Anti-SARS2-S antibodies
IL307175A (en) IL-38 specific antibodies
GB202116709D0 (en) Antibodies
GB202115824D0 (en) Antibodies
GB202112297D0 (en) Antibodies